ScienceDirect Maximizes Research Capabilities, Enhances the Research Process
New interactive and intuitive tools announced for Elsevier's online STM information platform
Amsterdam , October 22, 2007 - Elsevier, leading publisher of scientific, technical and medical (STM) information, today announced that it has added more development-partner-tested features on its ScienceDirect platform. Now well integrated in ScienceDirect product development, the development partners' involvement has ensured that the new features mirror researchers' needs.
"We are helping to foster scientific discovery by implementing new functionality that improves ways in which researchers find relevant content," explains Joep Verheggen, Director, ScienceDirect. "Our 'Related Articles' function broadens the initial search by automatically generating similar research results and our new spell checker saves time on re-entering search queries."
Through intelligent document matching, Related Articles automatically displays citation information and the abstract – including a link to the full text – of content relevant to the article being accessed. This improves the discoverability of information and makes it easier for a researcher to find key information.
To maximize search outcomes and eliminate unwanted results, a new Fast Search & Transfer™ (FAST) spell check function has been integrated into ScienceDirect. The spell checker recognizes spelling errors using a built-in dictionary.
As an added value to traditional abstracts, ScienceDirect is now indexing Graphical Abstracts of 30 chemistry titles. Particularly important to organic¹ chemistry researchers, Graphical Abstracts help researchers to summarize the scope of a structure or reaction more succinctly than plain text.
For more information on the latest additions to ScienceDirect, please visit: http://www.sciencedirect.info/news/releases/
¹Also of relevance to several other fields of chemistry, such as inorganic and materials chemistry.
Over a quarter of the world's full text scientific, technical and medical (STM) articles - managed by renowned editors, written by respected authors and read by researchers from around the globe - are available in one place: ScienceDirect.
Elsevier's extensive and unique full-text collection covers authoritative titles from the core scientific literature including high impact factor titles such as THE LANCET, Cell and Tetrahedron. Over eight million articles are available online, including Articles in Press which offer rapid access to recently accepted manuscripts. The critical mass of information available on ScienceDirect is unsurpassed. Coverage includes over 2,000 journals published by Elsevier and dynamic linking to journals from approximately 2,000 STM publishers through CrossRef. An expanding program of online major reference works, handbooks, book series and e-Books in all fields of science seamlessly interlinks with primary research referenced in journal articles.
Elsevier is a world-leading provider of scientific, technical and medical information products and services. The company works in partnership with the global science and health communities to publish more than 2,000 journals, including The Lancet and Cell, and close to 20,000 book titles, including major reference works from Mosby and Saunders. Elsevier’s online solutions include ScienceDirect, Scopus, SciVal, Reaxys, ClinicalKey and Mosby’s Suite, which enhance the productivity of science and health professionals, helping research and health care institutions deliver better outcomes more cost-effectively.
A global business headquartered in Amsterdam, Elsevier employs 7,000 people worldwide. The company is part of Reed Elsevier Group plc, a world leading provider of professional information solutions. The group employs more than 30,000 people, including more than 15,000 in North America. Reed Elsevier Group plc is owned equally by two parent companies, Reed Elsevier PLC and Reed Elsevier NV. Their shares are traded on the London, Amsterdam and New York Stock Exchanges using the following ticker symbols: London: REL; Amsterdam: REN; New York: RUK and ENL.
+31 20 485 2893